Evidence map›Paper›PMID 40471097›Full record

ReviewThe quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...2025

Combination prostate-specific membrane antigen-targeted radiopharmaceutical therapy in metastatic prostate cancer.

Hossein Jadvar, Kambiz Rahbar, Hojjat Ahmadzadehfar, Pedram Heidari, Shadi A Esfahani, Ali Afshar-Oromieh, Amir Iravani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hossein JadvarDivision of Nuclear Medicine and Molecular Imaging Center, Department of Radiology, Radiation Oncology and Urology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA - jadvar@med.usc.edu.
Kambiz RahbarDepartment of Nuclear Medicine and West German Cancer Center, University Hospital Munster, Munster, Germany.
Hojjat AhmadzadehfarDepartment of Nuclear Medicine, Knappschaft Kliniken, Dortmund, Germany.
Pedram HeidariDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Shadi A EsfahaniDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ali Afshar-OromiehDepartment of Nuclear Medicine, University Hospital, Bern, Switzerland.
Amir IravaniDivision of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, WA, USA.

Funding

Molecular Imaging of Fibrosis for Improved Treatment Planning of Pancreatic Ductal AdenocarcinomaK08CA259626 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Shadi Abdar Esfahani · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA259626
6 · The paper itself

Abstract

Radiopharmaceutical therapy is emerging rapidly as an effective and safe pillar in cancer management. The regulatory approvals for

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIMolecular Targeted TherapyProstatic NeoplasmsRadiopharmaceuticalsCombined Modality TherapyHumansMaleNeoplasm MetastasisAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIRadiopharmaceuticals

Identifiers

PMID40471097
PMCPMC13060771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.